Korro Bio initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald last night initiated coverage of Korro Bio (KRRO) with an Overweight rating and $74 price target Korro is a leading developer of RNA editing oligonucleotide therapeutics, the analyst tells investors in a research note. The firm says KRRO-110 could constitute the best approach for Alpha-1 antitrypsin deficiency, an “increasingly competitive but seemingly large indication.” Korro’s next clinical program could be in phenylketonuria or a similar condition, adds Cantor.